What is treatment success in cardiac resynchronization therapy?

被引:58
作者
Foley, Paul W. X. [1 ]
Leyva, Francisco [1 ]
Frenneaux, Michael P. [1 ]
机构
[1] Univ Birmingham, Queen Elizabeth Hosp, Dept Cardiol, Ctr Cardiovasc Sci, Birmingham B15 2TH, W Midlands, England
来源
EUROPACE | 2009年 / 11卷
关键词
Cardiac resynchronization therapy; Mortality; Responders; BRAIN NATRIURETIC PEPTIDE; CONGESTIVE-HEART-FAILURE; LONG-TERM SURVIVAL; DIASTOLIC VENTRICULAR INTERACTION; EXERCISE OXYGEN-CONSUMPTION; SURROGATE END-POINTS; 6-MINUTE WALK TEST; SYSTOLIC FUNCTION; PROGNOSTIC VALUE; CLINICAL-TRIALS;
D O I
10.1093/europace/eup308
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac resynchronization therapy (CRT) is an established treatment for symptomatic patients with heart failure, a prolonged QRS duration, and impaired left ventricular (LV) function. Identification of 'responders' and 'non-responders' to CRT has attracted considerable attention. The response to CRT can be measured in terms of symptomatic response or clinical outcome, or both. Alternatively, the response to CRT can be measured in terms of changes in surrogate measures of outcome, such as LV volumes, LV ejection fraction, invasive measures of cardiac performance, peak oxygen uptake, and neurohormones. This review explores whether these measures can be used in assessing the symptomatic and prognostic response to CRT. The role of these parameters to the management of individual patients is also discussed.
引用
收藏
页码:58 / 65
页数:8
相关论文
共 83 条
[81]   Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy [J].
Yu, CM ;
Bleeker, GB ;
Fung, JWH ;
Schalij, MJ ;
Zhang, Q ;
van der Wall, EE ;
Chan, YS ;
Kong, SL ;
Bax, JJ .
CIRCULATION, 2005, 112 (11) :1580-1586
[83]  
Zardini M, 2000, EUR HEART J SUPPL, V2, pJ16